Pharmaceuticals

Exploring Amgen’s Project Orbis experience with sotorasib (Part 2)

By , , , 2022-05-26T13:32:00

AdobeStock_286032180

Source: Adobe Stock

On 28 May 2021, sotorasib (LUMAKRAS™/LUMYKRAS®), a novel, first-in-class, inhibitor of the RAS GTPase family became the first drug to be approved by the US Food and Drug Administration (FDA) to target Kirsten rat sarcoma proto-oncogene (KRAS) G12C, a target that was considered undruggable for 40 years. Sotorasib is indicated ...

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community before
30 September and get 3 month’s extra membership for only £20.

Join by 30 September to get this exclusive rate.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Become a member today!

Have you heard? Why not listen to one of our free podcasts to see what you’re missing?